Source-grounded facts extracted from Phathom Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Phathom Pharmaceuticals, Inc. shareholders approved Approval of the Compensation of the Named Executive Officers ("say-on-pay") at the 2026-05-19 meeting.
“Proposal No. 3 – Approval of the Compensation of the Named Executive Officers (“say-on-pay”) The Company’s stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers: Votes For Votes Against Abstentions Broker Non-Votes 44,449,761 2,532,145 165,675 17,487,652”
Phathom Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-19 meeting.
“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026: Votes For Votes Against Abstentions 64,482,757 49,661 102,815”
Phathom Pharmaceuticals, Inc. shareholders approved Election of Class I Directors at the 2026-05-19 meeting.
“Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Directors Votes For Withheld Broker Non-Votes Steven Basta 42,656,800 4,490,781 17,487,652 Theodore R. Schroeder 42,578,532 4,569,049 17,487,652 Mark Stenhouse 41,249,990 5,897,591 17,487,652”
Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $58.3 million. Guidance reaffirmed.
“Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update • ~1.35 million total VOQUEZNA ® prescriptions filled to date • $58.3 million in Q1 net revenues, a 104% increase year-over-year • Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million,”
Theodore R. Schroeder was appointed as Director at Phathom Pharmaceuticals, Inc..
“The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025”
Steven Basta was appointed as Chief Executive Officer, President and Class I director at Phathom Pharmaceuticals, Inc..
“Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.”
Terrie Curran resigned as President and Chief Executive Officer at Phathom Pharmaceuticals, Inc..
“Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.”
Phathom Pharmaceuticals, Inc. reported the first quarter of 2024 results: revenue Net revenues for the first quarter 2024 were $1.9 million, net income Net loss for the first quarter 2024 was $82.9 million.
“Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024”
Phathom Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.7 million.
“Business Update • Launched VOQUEZNA ® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter • Early physician prescribing demonstrates strong demand for VOQUEZNA • Secured expanded commercial coverage for VOQUEZNA with a top U.S. pharmacy benefit”
Phathom Pharmaceuticals, Inc.: Amended and restated bylaws to address universal proxy rules, enhance procedural mechanics for stockholder nominations and proposals, and make technical updates (effective 2023-12-13).
“On December 13, 2023, the Board of Directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day.”
Phathom Pharmaceuticals, Inc. amended credit facility of increases the aggregate principal amount of the term loans from $200,000,000 to $300,000,000 with Hercules Capital, Inc. at reduces the cash interest rate from 10.75% ... to 9.85% (floating rate based on maturing extends ... the maturity date from October 2026 to December 2027.
“and the Lenders (the “Loan Agreement”). Amendments to Amount and Interest Rate . The Fourth Amendment, (i) increases the aggregate principal amount of the term loans from $200,000,000 to $300,000,000; (ii) provides for the possibility of accessing the $160 million currently undrawn commitment through five additional tranches referred to as tranches 2 through 6,”
Phathom Pharmaceuticals, Inc. amended Fourth Amendment to Loan and Security Agreement with Hercules Capital, Inc., as administrative agent, collateral agent and a lender, and the other lenders party thereto valued at increases the aggregate principal amount of the term loans from $200,000,000 to $300,000,000 (effective 2023-12-14).
“Phathom Pharmaceuticals, Inc. (the “Company”) entered into a Fourth Amendment to Loan and Security Agreement (the “Fourth Amendment”) with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender (in such capacity, the “Agent” or “Hercules”) and the other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the “Lenders”).”
Phathom Pharmaceuticals, Inc. reported the third quarter of 2023 results: net income $43.2 million.
“Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023”
Phathom Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income $41.0 million.
“Net loss for the second quarter ended June 30, 2023, was $41.0 million, compared to $50.9 million for second quarter 2022.”
Phathom Pharmaceuticals, Inc.: Amendment to certificate of incorporation to eliminate personal liability of officers for monetary damages for breach of fiduciary duty (effective 2023-05-26).
“On May 25, 2023, Phathom Pharmaceuticals, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, as described below under Item 5.07, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, to eliminate the personal liability of the Company’s officers for monetary damages for breach of fiduciary duty as an officer, except to the extent such an exemption from liability or limitation thereof is not permitted by Delaware General Corporation Law (the “Amendment”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on May 26, 2023 (“Certificate of Amendment”).”
Phathom Pharmaceuticals, Inc. shareholders approved Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation limiting the liability of certain officers at the 2023-05-25 meeting.
“Proposal No. 3 – Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation limiting the liability of certain officers of the Company: Votes For Votes Against Abstentions 30,144,733 2,102,985 7,691”
Phathom Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-05-25 meeting.
“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2023: Votes For Votes Against Abstentions 38,861,215 20,414 5,983”
Phathom Pharmaceuticals, Inc. shareholders approved Election of Class I Directors at the 2023-05-25 meeting.
“Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Directors Votes For Withheld Broker Non-Votes Terrie Curran 32,159,915 95,494 6,632,203 Mark Stenhouse 28,966,136 3,289,273 6,632,203”
Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income $37.8 million.
“Net loss for the first quarter ended March 31, 2023 was $37.8 million, compared to $40.7 million for first quarter 2022.”
Phathom Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter ended December 31, 2022 was $55.0 million.
“On February 28, 2023, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
Phathom Pharmaceuticals, Inc. reported the third quarter of 2022 results: net income Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter.
“On November 8, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Phathom Pharmaceuticals, Inc. amended Joinder and Waiver Agreement with entities managed or advised by NovaQuest Capital Management, Sagard Holdings Manager LP, Hercules Capital, Inc., and CO Finance LVS XXXVII LLC (effective 2022-10-31).
“On October 31, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) entered into a Joinder and Waiver Agreement with (a) entities managed or advised by NovaQuest Capital Management (“NQ”), Sagard Holdings Manager LP (“Sagard”), and Hercules Capital, Inc. (“Hercules,” together with NQ and Sagard, the “Initial Investors”), (b) CO Finance LVS XXXVII LLC (the “Additional Investor”), (c) Hercules Capital, Inc. in its capacity as administrative agent and collateral agent for itself and the lenders under that certain Loan and Security Agreement, dated as of September 17, 2021, and the other entities set forth on the signature pages thereto (the “Joinder and Waiver Agreement”) in respect of the Revenue Interest Financing Agreement, entered into on May 3, 2022 (the “Revenue Interest Financing Agreement”).”
James Topper, M.D., Ph.D. was appointed as Class III Director at Phathom Pharmaceuticals, Inc..
“On September 22, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed James Topper, M.D., Ph.D. to the Board as a Class III director, effective immediately, with an initial term expiring at the 2025 annual meeting of stockholders of the Company.”
Frank Karbe was appointed as Director at Phathom Pharmaceuticals, Inc..
“On April 25, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Frank Karbe to the Board as a Class II director, effective immediately”
Molly Henderson was appointed as Chief Financial and Business Officer at Phathom Pharmaceuticals, Inc..
“On March 22, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) announced the appointment of Molly Henderson, 51, as its Chief Financial and Business Officer effective April 5, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.